Xofluza (Baloxavir Marboxil) is a new type of anti-influenza virus drug, which has attracted widespread attention due to the convenience of single oral administration. Understanding its potential side effects, being alert to severe adverse reactions, and mastering the precautions for medication use are crucial for the safety of its treatment.

What are the Side Effects of Xofluza (Baloxavir Marboxil)?

Gastrointestinal Reactions

Diarrhea: The incidence rate is approximately 1.8% in adults and adolescents aged 12 and above, making it the most common side effect.

Nausea and Vomiting: The incidence rate can reach 2.2% in patient groups with high-risk factors.

The incidence of gastrointestinal symptoms in pediatric patients is relatively low (3.8% for tablets and 3.0% for granules).

Allergic Reactions

Rash and urticaria (incidence rate < 1%).

Pruritus and angioedema (frequency unknown).

Abnormal Liver Function Indicators

Elevated ALT and AST (incidence rate < 1%).

Severe Side Effects of Xofluza (Baloxavir Marboxil)

Shock and Allergic Reactions

Although the occurrence frequency is unknown, it may progress rapidly. Immediate drug withdrawal and medical attention are required.

Abnormal Behaviors

During the influenza illness period, abnormal behaviors such as sudden running and wandering may occur, especially with a higher risk in school-age and underage males.

Mental status should be closely monitored during medication use, and activities at heights should be avoided.

Ischemic Colitis

It is characterized by symptoms such as abdominal pain and bloody stools. Once it occurs, immediate colonoscopy and intervention are necessary.

Bleeding Tendency

Clinical manifestations include bloody stools, epistaxis, hematuria, etc.

Neonates and infants may be at risk of vitamin K deficiency.

It is necessary to confirm whether vitamin K preparations are supplemented before medication use.

Symptoms may appear a few days after medication use.

Precautions for Xofluza (Baloxavir Marboxil)

Pediatric Population

There is a lack of clinical trial data for low-birth-weight infants and neonates.

Special caution is required when administering the drug to children with a body weight of less than 20 kg, and other anti-influenza drugs should be given priority.

Pregnant and Lactating Women

Pregnant women need to be strictly evaluated for the benefits and risks of medication use.

Lactating women should be comprehensively evaluated for the necessity of treatment and consider suspending breastfeeding.

Contraindications

It is contraindicated for patients with a history of allergy to any component of this product.

Combined Medication Warnings

Warfarin: It may prolong the prothrombin time, so close monitoring of coagulation function is required.

Itraconazole (a P-glycoprotein inhibitor): It may increase the blood concentration of this drug.

Administration Timing

Therapeutic medication should be initiated within 48 hours after the onset of symptoms.

Prophylactic medication should be initiated within 48 hours after contact with an infected person.